Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global Radiation Therapy Systems Market Expected to Reach $5.6B by 2020

Executive Summary

Although immunotherapy and other cutting-edge technologies have dominated the spotlight in cancer treatment over the last several years, the use of radiation therapy is rapidly increasing as physicians look to this non-invasive, cost-effective treatment to address a broad and growing number of cancers. Valued at nearly $4.3 billion in 2015, the global radiation therapy market is growing at a CAGR of 5.5%, and is projected to reach $5.6 billion by 2020, according to a recent report from Medtech Insight.

You may also be interested in...



WashU Researchers Plan Major Trial Of Noninvasive Radiation Ablation For Ventricular Tachycardia

Physicians developing a promising technique for noninvasive cardiac radioablation for ventricular tachycardia are working with US FDA to develop a large multicenter trial of their technique following the success of a five-patient case-series and an 18-patient prospective study. 

Can Pencil Beam Proton Therapy Revolutionize Cancer Care?

In the billion dollar market for radiotherapy products, pencil beam proton therapy could potentially revolutionize cancer care but the technology is very expensive, and it remains to be seen how many medical institutions in the US and worldwide will be interested in adopting the large systems, which require years to construct. Scripps Proton Therapy Center medical director Carl Rossi, MD, speaks about the benefits of proton therapy compared with other types of radiation therapy.

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel